Miguel Corona Guzman

US Patent:

20220226301, Jul 21, 2022

Filed:

Mar 30, 2022

Appl. No.:

17/708732

Inventors:

- Newark CA, US
Carlos SCHULER - Kensington CA, US
Miguel GUZMAN - San Jose CA, US

International Classification:

A61K 31/4458
A61K 31/18
A61K 31/167
A61K 31/138
A61P 9/06

Abstract:

Disclosed herein are methods and kits for treating or preventing a heart condition, e.g., cardiac arrhythmia, e.g., atrial arrhythmia, using potassium channel inhibitors and class I antiarrhythmic agents. Also disclosed herein are methods and kits for treating a heart condition via an intravenously, orally, or inhalationally administered fixed-dose combination of a sodium channel blocker and a class I antiarrhythmic agent.

US Patent:

20190169188, Jun 6, 2019

Filed:

Oct 25, 2018

Appl. No.:

16/171124

Inventors:

- Los Gatos CA, US
Geoff McKinley - Mountain View CA, US
Scott Borland - Los Gatos CA, US
Miguel Guzman - Cupertino CA, US
Ármin Szabolcs - Szombathely, HU
János Gerencser - Budapest, HU

International Classification:

C07D 471/06
C07D 495/06

Abstract:

Provided herein are ergoline compounds and pharmaceutical compositions thereof. In some embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT, 5-HTand 5-HTreceptors without agonizing the 5-HTreceptor using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HTadrenergic alphaand/or the alphareceptors using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the D2 and D3 receptor using the compounds and pharmaceutical compositions disclosed herein.

US Patent:

20180327404, Nov 15, 2018

Filed:

Apr 3, 2018

Appl. No.:

15/943714

Inventors:

- Los Gatos CA, US
Geoff McKinley - Mountain View CA, US
Scott Borland - Los Gatos CA, US
Miguel Guzman - Cupertino CA, US
Ármin Szabolcs - Szombathely, HU
János Gerencser - Budapest, HU

Assignee:

Xoc Pharmaceuticals, Inc. - Los Gatos CA

International Classification:

C07D 471/06
C07D 495/06

Abstract:

Provided herein are ergoline compounds and pharmaceutical compositions thereof. In some embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT, 5-HTand 5-HTreceptors without agonizing the 5-HTreceptor using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HTadrenergic alphaand/or the alphareceptors using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the D2 and D3 receptor using the compounds and pharmaceutical compositions disclosed herein.

US Patent:

20180298001, Oct 18, 2018

Filed:

Jun 22, 2018

Appl. No.:

16/016474

Inventors:

- Los Gatos CA, US
Geoff McKinley - Mountain View CA, US
Scott Borland - Los Gatos CA, US
Miguel Guzman - Cupertino CA, US
Ármin Szabolcs - Szombathely, HU
János Gerencser - Budapest, HU

International Classification:

C07D 471/06
C07D 495/06

Abstract:

Provided herein are ergoline compounds and pharmaceutical compositions thereof. In some embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT, 5-HTand 5-HTreceptors without agonizing the 5-HTreceptor using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HTadrenergic alphaand/or the alphareceptors using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the D2 and D3 receptor using the compounds and pharmaceutical compositions disclosed herein.

US Patent:

20170233387, Aug 17, 2017

Filed:

May 3, 2017

Appl. No.:

15/586244

Inventors:

- Los Gatos CA, US
Geoff McKinley - Mountain View CA, US
Scott Borland - Los Gatos CA, US
Miguel Guzman - Cupertino CA, US

Assignee:

Xoc Pharmaceuticals, Inc. - Los Gatos CA

International Classification:

C07D 457/12

Abstract:

Provided herein are isoergoline compounds and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT, 5-HTand 5-HTreceptors without agonizing the 5-HTreceptor using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HTadrenergic alphaand/or the alphareceptors using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the D2 and D3 receptor using the compounds and pharmaceutical compositions disclosed herein.

US Patent:

20170233404, Aug 17, 2017

Filed:

May 3, 2017

Appl. No.:

15/586255

Inventors:

- Los Gatos CA, US
Geoff McKinley - Mountain View CA, US
Scott Borland - Los Gatos CA, US
Miguel Guzman - Cupertino CA, US

Assignee:

Xoc Pharmaceuticals, Inc. - Los Gatos CA

International Classification:

C07D 495/06
C07D 471/06

Abstract:

Provided herein are isoergoline compounds and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT, 5-HTand 5-HTreceptors without agonizing the 5-HTreceptor using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HTadrenergic alphaand/or the alphareceptors using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the D2 and D3 receptor using the compounds and pharmaceutical compositions disclosed herein.

US Patent:

20170174684, Jun 22, 2017

Filed:

Mar 3, 2017

Appl. No.:

15/448951

Inventors:

- Los Gatos CA, US
Geoff McKinley - Mountain View CA, US
Scott Borland - Los Gatos CA, US
Miguel Guzman - Cupertino CA, US
Ármin Szabolcs - Szombathely, HU
János Gerencser - Budapest, HU

Assignee:

Xoc Pharmaceuticals, Inc. - Los Gatos CA

International Classification:

C07D 471/06

Abstract:

Provided herein are ergoline compounds and pharmaceutical compositions thereof. In some embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT, 5-HTand 5-HTreceptors without agonizing the 5-HTreceptor using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HTadrenergic alphaand/or the alphareceptors using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the D2 and D3 receptor using the compounds and pharmaceutical compositions disclosed herein.

US Patent:

20170174685, Jun 22, 2017

Filed:

Mar 3, 2017

Appl. No.:

15/449018

Inventors:

- Los Gatos CA, US
Geoff McKinley - Mountain View CA, US
Scott Borland - Los Gatos CA, US
Miguel Guzman - Cupertino CA, US
Armin Szabolcs - Szombathely, HU
János Gerencser - Budapest, HU

Assignee:

Xoc Pharmaceuticals, Inc. - Los Gatos CA

International Classification:

C07D 471/06

Abstract:

Provided herein are ergoline compounds and pharmaceutical compositions thereof. In some embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT, 5-HTand 5-HTreceptors without agonizing the 5-HTreceptor using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HTadrenergic alphaand/or the alphareceptors using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the D2 and D3 receptor using the compounds and pharmaceutical compositions disclosed herein.

Address:

4910 2 Ave, Los Angeles, CA 90043

Phone:

(213)2487785

VIN:

1FTEW1C88AKB24812

Make:

FORD

Model:

F-150

Year:

2010

Address:

517 Williamson Ave, Los Angeles, CA 90022

VIN:

1G1AL58FX87191097

Make:

CHEVROLET

Model:

COBALT

Year:

2008